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I. INTRODUCTION 
 Diffuse   parenchymal lung diseases  (DPLD)  are   a diverse  group of pulmonary 
disorders that are classified together because of similar clinical, roentgenographic, 
physiologic, or pathologic manifestations1. They are also referred to as  interstitial lung 
diseases  (ILD).DPLD alter mechanical and gas exchange properties of the lungs. In 
general, the hall marks of DPLD are restrictive changes in pulmonary physiology i.e 
decreased total lung capacity, reduced residual volume, diminished static compliance and 
reduced vital capacity often with an increased FEV1/FVC ratio and a reduced diffusing 
capacity with carbon monoxide. 
 Hence pulmonary function testing (PFT)  aids in the evaluation and management 
of patients with DPLD by provide an estimate of histologic severity, baseline estimation 
of prognosis and be used to monitor disease progression or response to therapy. The 
forced vital capacity and diffusion capacity are the most valuable serial measurements for 
diagnosing DPLD. 
  The collagen vascular diseases are a heterogeneous group of immunologically 
mediated inflammatory diseases. It is not surprising that, by virtue of their abundant 
connective tissue and blood supply, the lungs are frequently involved in these disorders. 
Consequently, collagen vascular diseases  affect  all  areas of the lung (i.e. airways,  
alveoli, vascular system, and pleura), and do so in various degrees and combinations2. 
 Diffuse parenchymal lung diseases in CVD patients are characterised by 
deteriorating parenchymal fibrosis and gas exchange. It remains innocuous in the early 
stage, as most of the rheumatic patients have restricted mobility manifesting with subtle 
or nil pulmonary symptoms. Hence, the respiratory physician should be prudent in 
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diagnosing the cases as early as possible. Because the  pulmonary specialist often 
involved in care of these patients, a comprehensive understanding of  collagen vascular 
disease and  usual course of  Diffuse  parenchymal lung diseases  are important.  
 The clinical assessment of a patient with DPLD requires a combination of history 
and physical examination, laboratory investigation, lung function testing, chest imaging 
studies, bronchoalveolar lavage, and histological examination. 
 Over the last few years, the abnormal patterns of DPLD on High Resolution 
Computerised Tomography (HRCT) scans have been refined and are increasingly 
recognised as diagnostic patterns. This has led to the increasing use of HRCT scans in 
conjunction with thorough clinical assessment3. By pulmonary function tests (PFT) the 
severity of physiologic disarrangements in DPLD, correlate well with the overall extent 
of pathologic and HRCT abnormalities4. Abnormalities of pulmonary function tests also 
verify the presence of disease particularly in those patients with normal chest 
roentgenograms.  
  This study throws light on the non-invasive procedures rather than the invasive 
procedures. Since most of the patients deny procedures like bronchoscopy or surgical 
biopsy  as well as they are in real respiratory compromise, it is better to opt an alternate 
procedure like HRCT , Diffusing capacity for carbon monoxide (DLCO) and spirometry  
which are frequently done nowadays as an adjunct to aid the diagnosis. 
 
 
 3
II. AIM OF THE STUDY 
To evaluate the Diffusing capacity for carbon monoxide among patients with 
Diffuse parenchymal lung disease in proven Rheumatologic illness showing various 
pattern of abnormalities in the High Resolution Computerised Tomography and correlate 
the same with spirometry. 
DESIGN OF THE STUDY: 
 Prospective study. 
 Approval from Medical Ethical Committee has been obtained. 
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III. REVIEW OF LITERATURE 
Diffuse parenchymal lung diseases (DPLD) commonly complicate the  
management of collagen  vascular diseases. Hence a comprehensive understanding of    
collagen vascular disease and the usual cause of diffuse parenchymal lung disease is   
important. Approximately 15% of the patients who present with diffuse parenchymal  
lung diseases have an underlying collagen vascular disease5. Furthermore clinical  
symptoms like cough, dyspnoea or Diffuse Parenchymal Lung Disease may be   the   first   
manifestation of  Rheumatic diseases. Finally it can result in significant morbidity   and   
mortality. 
 The  autoimmune mediated inflammation and  fibrosis   that  characterises these 
diseases can easily and irreversibly disrupt the normal functioning of the lung. As a  
group they can affect each portion of the lung :- The pleura, alveoli, interstitium, 
vasculature,   lymphatic tissue  and   of  both small  and larger airways. The lung diseases 
associated  with   collagen  vascular  disease  may  precede  the   clinical  presentation  of 
collagen  vascular  disease   by  five  years  or  more5. 
Full pulmonary function tests (PFT) should be performed in all cases of suspected 
DPLD with collage vascular diseases. They aid in the diagnosis DPLD, assessment of 
disease severity, response to treatment, and prognosis. DLCO is typically reduced in 
DPLD to greater extent than the lung volumes at which it is measured. Co-existence of 
DPLD with obstructive airway disease (i.e.emphysema), can confuse the results with a 
mixed pattern of restriction observed as reduced lung volumes and obstruction 
manifesting as a reduced FEV1/FVC ratio. 
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 Baseline PFT may provide an estimate of prognosis. Exertional oxygen 
desaturation to less than 88% and a decrease in FVC (greater than 10%) over a short 
follow up period predict patients at increased risk of mortality. Severely decreased DLCO 
(<30%) is also associated with increased mortality. Serial PFTs provide valuable 
information in determining disease progression and response to medication. FVC and 
DLCO are the most valuable serial measurements. 
Many of these Collagen vascular diseases are characterised by the presence of the 
specific type of autoantibody that may greatly assist in specific diagnosis. 
AUTO ANTIBODY  ASSOCIATED  WITH  SPECIFIC COLLAGEN VASCULAR 
DISEASES7 
Diseases Associated Antibodies 
Rheumatoid Arthritis 
Systemic sclerosis 
 
Mixed connective tissue diseases       
Dermatomyositis/Polymyositis 
Systemic lupus erythematosus 
 
Sjogren’syndrome 
 
 
Rheumatoid factor 
Antiscl-70 
Anticentromere Antibody 
Anti ribonuclear protein 
Anti-Jo-1 
Anti-ds-DNA 
Anti-sm 
Anti ss-A(Ro)  
Anti ss-B(La)  
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The  association  of   Collagen  vascular  disease  and  Diffuse  parenchymal lung 
disease  (DPLD)  is  well  established6.  DPLD  complicating  collagen vascular diseases 
account  for  high  morbidity  and  mortality.  Until  recently,  most  of the studies of lung 
involvement  in   the   collagen  vascular  disease  relied    on  clinical,   physiological  
and radiological  data   to  define  the   presence  of  disease,  determine  the clinical 
course, and assess  the  prognosis  of  the  lung  involvement.  
RHEUMATOID ARTHRITIS  (RA) 
It    is  a    sub acute   or  chronic  inflammatory   polyarthropathy  of   unknown   
cause  that particularly affects peripheral joints. Lung fibrosis associated with 
Rheumatoid arthritis   was  first   reported  by  Ellman & Ball  19488.  
DPLD quickly appeared as the predominant pulmonary manifestation of 
rheumatoid arthritis (RA) (after excluding drug-induced pulmonary disease).Systematic 
PFTs detected a decreased diffusing capacity(DLCO) in 41% of patients, and among 
them, 50% exhibited features of fibrosis associated with lymphoid infiltrates in lung 
biopsy. Dawson and colleagues studied 29 patients with RA and found that DLCO < 54% 
of predicted had an 80% sensitivity and a 93% specificity for predicting progressive 
parenchymal lung disease over the next 2 years. 
Prevalence of pleuropulmonary manifestations is clearly increased in males and in 
smokers. Coexisting subcutaneous rheumatoid nodules, high titres of circulating 
rheumatoid factor or antinuclear antibodies are also considered significant risk factors 
while the incidence of DPLD appears unrelated to the severity of articular disease. 
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Rheumatoid lung fibrosis is twice as common in men as in women with a mean 
age of  about fifty years. RA is characterised by the presence of  symmetric arthritis,  
morning stiffness and Rheumatoid factor in the blood. 
Pleuropulmonary complications include interstitial pneumonitis with fibrosis, 
Rheumatoid (necrobiotic) nodules,  Bronchiolitis Obliterans Organising Pneumonia, 
Bronchiectasis, Obliterative bronchiolitis,  follicular bronchiolitis and pleural effusion or 
pleural thickening 9,10. 
Interstitial pneumonitis with fibrosis are the most common pulmonary 
manifestations of Rheumatoid arthritis9.In fact  pulmonary function abnormalities 
consistent with interstitial fibrosis have been reported in as many as 40% of patients who 
have Rheumatoid arthritis9.In more than half of these patients, however finding at chest 
roentgenogram are normal. Evidence of interstitial fibrosis is seen at chest roentgenogram 
in approximately 5%9 and at HRCT in 30% to 40%10 of patients with RA. The 
complication is seen most frequently on men between 50 and 60 years of age. 
TYPES OF INTERSTITIAL PNEUMONIA 
 Non-specific interstitial pneumonia(NSIP),Usual interstitial pneumonia(UIP) 
 Cryptogenic organising pneumonia(COP) and 
 Lymphocytic interstitial pneumonia(LIP).  
 The majority of the patients with interstitial fibrosis associated with RA have UIP, 
and only a small percentage have histological findings of  NSIP. Nodular aggregates of  
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lymphocytes may be prominent in both the parenchymal interstitium and in the interstitial 
tissue in bronchiolar walls and interlobular septa(Follicular bronchiolitis). 
RADIOLOGIC MANIFESTATIONS 
 Initial radiographic studies found a low incidence of 1.6–5% of DPLD in RA8. In 
the early stage, the radiographic appearance consists of  irregular linear hyper attenuating 
areas in a fine reticular pattern. The abnormality usually involves mainly the lower lung 
zones. With the progression of disease, the reticular pattern becomes coarser and diffuse 
and later honeycombing may be seen11.  
HRCT FINDINGS 
HRCT findings consist of irregular linear hyper attenuating areas caused by a 
combination of intralobular lines and irregular thickening of  interlobular septa10. 
Honeycombing is seen more markedly near the diaphragm. HRCT demonstrates 
interstitial lung disease in patients with or without clinical evidence of the disease (69%–
80% and 20%–29% respectively) 10. 
 In a study by Akira et al, three major radiographic patterns of disease have been 
identified in symptomatic patients who developed lung disease prior to or following the 
diagnosis of RA12. These include reticulation with or without honeycombing (66% 
patients), centrilobular branching lines with or without bronchial dilatation (17%), and 
consolidation (17%). 
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SPIROMETRY IN RA 
The physiologic abnormalities of rheumatoid DPLD are identical to the other 
fibrosing lung diseases13. There is a reduction in pulmonary compliance and lung 
volumes. Physiologic testing also often shows evidence of obstruction to airflow, which 
may reflect other pulmonary manifestations of RA including bronchiectasis, bronchiolitis 
obliterans, chronic airway obstruction or cricoarytenoid arthritis 14,15. 
DLCO IN RA 
 Abnormalities of gas transfer including a low DLCO is present  in RA. Abnormal 
pulmonary function may be found in individuals with normal chest roentgenograms14.  
SYSTEMIC SCLEROSIS (SS) 
It is a generalised collagen vascular disease characterised by the synthesis and 
deposition of excessive extracellular matrix and vascular obliteration in various organs16.  
Dr. Charlie Strange from the Medical University of South Carolina provided an 
algorithm for the management of DPLD in scleroderma patients that includes chest x-
rays, spirometry, and DLCO. If the results are normal, these tests should be repeated on a 
6-month basis. If any of the findings are abnormal, an HRCT should be obtained. All 
patients with scleroderma undergo annual echocardiography and measurements of their 
DLCO. A DLCO < 40% of predicted appears to be predictive for underlying Pulmonary 
Arterial Hypertension(PAH), and an FVC/DLCO ratio >1.8 has good performance 
characteristics in PAH.  
SS is divided into two broad categories: Diffuse and limited forms based on the 
extent of  cutaneous involvement , different clinical course and prognosis.  
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Most common clinical manifestations are 
 Tightening, induration and thickening of the skin (SCLERODERMA), 
 Raynaud’s and other vascular anomalies, 
 Musculoskeletal manifestation and 
Visceral involvement particularly Gastro Intestinal Tract, Lungs, Heart and 
Kidney. 
The diagnosis can be made with a high degree of certainty if the single major 
criterion of proximal scleroderma is present or if there are 2 or more minor criteria 
(sclerodactaly, pitting scars or loss of the substance of fingertips and bilateral basal 
pulmonary fibrosis)8. Systemic Sclerosis has 3:1 female to male distribution and presents 
more commonly in the third to fifth decade of life.  
Lung is the fourth most commonly affected structure after skin, vessel and 
oesophageal involvement7. Pulmonary involvement is more common and more severe in 
systemic sclerosis than in other types of collagen vascular disease. Prognostic factors for 
poor outcomes include male sex, the presence of lung involvement early in disease, low 
DLCO, severe Raynaud’s phenomenon, and cigarette smoking.   
RADIOLOGIC MANIFESTATIONS 
 Pulmonary fibrosis is the most common radiographic finding, present in 
20% –65% of patients 16, 17. The fibrosis usually has a basilar predominance and appears 
initially as a fine reticular pattern that progresses to coarse reticulation and 
honeycombing 16.  Pulmonary fibrosis is equally likely in the limited and diffuse forms of 
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the disease but is less severe in the limited form. In Schurawitzki H, Stiglbauer R, 
Graninger W, et al prospective study of 23 patients with systemic sclerosis, fibrosis was 
identified at chest radiography in 39% of patients and at high-resolution CT in 91% of 
patients 17. 
HRCT FINDINGS 
The predominant abnormalities at high-resolution CT consist of areas of ground-
glass attenuation, poorly defined sub pleural nodules, reticular pattern of attenuation, 
honeycombing, and traction bronchiectasis 17. 
 In Kim et al18 longitudinal CT series of 40 patients with SS study  , a variety of 
radiological features were found including ground-glass opacity (100%), irregular linear 
opacity (90%), small nodules (70%), honeycombing (33%), traction bronchiectasis 
(68%), bilateral pleural thickening (45%), and enlarged mediastinal lymph nodes (15%). 
After a mean follow-up of 40 months, regardless of the initial findings or presence of 
treatment, the extent of parenchymal disease, including ground-glass opacity and 
honeycombing, significantly increased with concomitant declines in forced expiratory 
volume in 1 second (FEV1), and forced vital capacity (FVC) without significant change 
in DLCO18. 
SPIROMETRY IN SS 
 Physiological studies have shown a restrictive pattern with a decreased total lung 
capacity (TLC), vital capacity (VC), forced vital capacity (FVC) and residual volume. 
The greatest decline in lung function occurs within the first 4 years of disease and 
moderate (forced vital capacity [FVC] 50-75% predicted) or severe (FVC< 50% 
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predicted) restrictive lung disease is detectable in approximately 40% of patients with 
scleroderma. Initially, there may be a reduction in DLCO, which may even precede 
symptoms onset and/or loss of lung volume.  Occult pulmonary impairment may be 
present in patients with normal pulmonary function tests (PFT) which may be 
demonstrated by cardio-respiratory exercise testing 19. 
DLCO IN SS 
 In SS impairment of the transfer factor (or diffusing capacity) for carbon 
monoxide (DLCO) is present. A reduced DLCO is the most common and most sensitive 
PFT abnormality in patients with scleroderma and has been shown to correlate with the 
presence of dyspnoea and with autopsy, evidence of DPLD. With progression of the 
DPLD, the restrictive pattern is paralleled by the decrease in gas exchange. As 
demonstrated by WELLS et al.20, DLCO is the best index of the extent of the DPLD 
when compared with HRCT as the "gold standard". Interestingly, patients with DPLD-
scleroderma have a better survival rate (86% at 5 yrs) than patients with idiopathic 
pulmonary fibrosis (IPF) (50% at 5 yrs) 21. 
Reduced DLCO in SS  
1. Related to alveolar septal thickening and vascular obliteration 
2. May be the earliest PFT abnormality and the most sensitive indicator of  SS 22 
3. Degree of decline corresponds to the severity of  dyspnoea 
4. Severe isolated reduction in DLCO (<45% of the predicted value) is an early 
     indicator of  Pulmonary arterial Hypertension23. 
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A low DLCO is more common in limited form than in diffuse form. FVC and 
DLCO are important prognostic factors  in scleroderma24. 
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 
 The    original   description  of    SLE   is  credited  to  Kaposi  in  1872.25.  It  is  a 
multisystem  disorder   that   particularly  affects  vessel,  serosa, kidneys, central nervous 
system,   skin , blood vessels,  joints  and  lung.  SLE  is  characterised   by   the  presence 
of   anto antibodies  against various  nuclear  antigens.  It   predominantly  affects   
women (F:M ratio 10:1)  aged   20–50 years.    
During   the  course  of   SLE,  pleural disease develops in 50%  of patients 26. 
Pulmonary parenchymal abnormalities are also common. Pleuropulmonary involvement 
occurs in approximately 50%–60% of patients. In one prospective study that included 
1,000 patients, lung involvement was identified in only 3% at the onset of the disease; it 
developed in an additional 7%  of patients over the period of observation . Parenchymal 
opacification may be caused by pneumonia, haemorrhage, acute lupus pneumonitis, or 
pulmonary oedema, with pneumonia being the most common cause 26. 
Pulmonary manifestations of systemic lupus erythematosus comprise both acute 
and chronic lesions. Acute disease includes pulmonary haemorrhage, acute lupus  
pneumonitis  and pulmonary oedema. Chronic disease such as interstitial pneumonitis 
with fibrosis  is less common than in other connective tissue disorders 27. 
 Most   frequent  lung   manifestation   in   SLE   results   from   acute   injury to 
the   alveolar-capillary  unit,   leading to acute lupus pneumonitis and/or alveolar 
haemorrhage 28,29. Acute lupus pneumonitis is an abrupt febrile pneumonic process 
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without infectious aetiology. The alveolar haemorrhage varies from mild to massive, and 
BAL studies often reveal haemosiderin-laden macrophages. It presents with dyspnoea, 
tachycardia, cough, fever, pleuritic chest pain and sometimes haemoptysis.  
ACUTE LUPUS PNEUMONITIS  
Acute lupus pneumonitis is characterized by the acute or sub acute onset of 
tachycardia, tachypnea, dyspnoea, cyanosis, and cough. Fever is common, but 
haemoptysis is infrequent, and clubbing is absent. The mean age in one series was 38 
years with a mean duration of known SLE of 16 months (range 0 to 48 months). In 50% 
of these patients, pneumonitis was the presenting manifestation of their SLE. Chest 
examination may reveal fine or coarse rales, but signs of pleurisy are rare. In severe 
cases, evidence of right ventricular overload may appear.  
The chest radiograph plays a limited role in the differential diagnosis of 
pulmonary complications of SLE. The most common findings in patients with SLE are 
non-specific areas of air space consolidation. The consolidation may be unilateral or 
bilateral and focal or diffuse, but it tends to involve mainly the lower lung zones. The 
most common cause of consolidation is pneumonia  
Chest roentgenograms in the acute lupus syndrome demonstrate diffuse or patchy 
opacities that are predominantly basilar, although the middle and upper zones may be 
affected. Usually bilateral, the opacities may be accompanied by pleural effusion and 
cardiomegaly. A recent case report described acute lupus pneumonitis in a patient with a 
normal chest radiograph and HRCT scan. Sub acute cases may demonstrate the 
migratory, recurrent, and polymorphic densities. Marked hypoxemia and hyperventilation 
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are often described in acute pneumonitis. Such deficits in particular cause an elevation of 
the alveolar-arterial gradient; persist in the majority (of a small number) of patients 
despite the apparent resolution of their lung disease. 
RADIOLOGIC MANIFESTATIONS 
 The most common radiographic manifestation is unilateral or bilateral pleural 
effusion that is frequently associated with pericardial effusion30 .Chest radiographs 
typically show unilateral or bilateral patchy areas of consolidation, mostly predominant in 
the lung bases, which may be associated with pleural effusion or atelectasis. Other chest 
radiographic findings of SLE  include loss of lung volume related to diaphragmatic 
dysfunction, pulmonary oedema, musculoskeletal changes related to renal failure, and 
bone changes related to corticosteroid therapy. 
HRCT FINDINGS 
 Multiple patterns have been reported in SLE . The most common findings are 
intralobular interstitial thickening and irregular thickening of the interlobular septa that 
are predominantly found in the lower lobes31,32. Other common findings on HRCT 
include traction bronchiectasis (architectural distortion and bronchial dilatation secondary 
to the fibrosis), small foci of air space consolidation, and areas of ground-glass 
attenuation31,32. Honeycombing changes may be present. Both pleural effusions and 
cardiomegaly may be noted. Enlargement of the pulmonary artery accompanies cor 
pulmonale. 
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SPIROMETRY & DLCO IN SLE 
 Several studies indicate that physiologic abnormalities (e.g., DLCO, lung 
volumes, or compliance) are more common than clinical or roentgenographic changes 33. 
Most common physiologic deficit in patients with SLE is the reduction in DLCO with or 
without decreased total lung capacity. Among patients with normal chest 
roentgenograms, a reduction in VC was noted in 27% and in DLCO in 67% 34. In two 
series of unselected patients, a reduction in DLCO occurred more frequently (72 to 80%) 
than did volume restriction (43 to 49%) or roentgenographic abnormalities (30 to 50%)35.  
POLYMYOSITIS/DERMATMYOSITIS (PM/DM) 
Polymyositis is an autoimmune inflammatory myopathy characterised by 
presence of symmetric weakness of the limb girdle and anterior neck muscles36. 
Dermatomyositis is similar to polymyositis except for the presence of a characteristic 
skin rash. PM/DM have an incidence of approximately 5–10 cases per million per year36 
and occur twice as often in women as in men. The diagnostic criteria for PM/DM are 
proximal muscle weakness (Symmetric, present  for weeks or months) , Muscle biopsy 
showing necrobiotic and inflammatory changes, Raised muscle enzymes ( Creatinine 
phosphokinase), Characteristic electromyography and Characteristic skin rash. In 
Dermatomyositis additional characteristic skin changes present: Heliotrope periorbital 
rash and violaceous/red papular rash over bony prominence.  
PM/DM is often associated with clinical, radiological or functional evidence of 
pulmonary fibrosis. Mills and Mathews first described interstitial fibrosis in 
Dermatomyositis in 1956. In two retrospective studies, DPLD were found in 5% of  PM 
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and 9% of DM cases3. Lung involvement in PM/DM may precede muscle or skin 
manifestations in 33% of cases. There is no correlation between the extent and severity of 
muscle and skin involvement and the development of DPLD.  
The clinical presentation may be arbitrarily divided into three forms.  
1) DPLD may occasionally be rapidly progressive with acute fever, dyspnoea and 
lung infiltrates similar to a Hamman-Rich-syndrome. 
2) Patients may have a slowly progressive dyspnoea upon exertion with chest 
radiographic abnormalities. 
3) Some patients may have no pulmonary symptoms, but abnormal radiographs 
and/or PFT. 
RADIOLOGIC MANIFESTATIONS  
Chest radiographs most often reveal bilateral basal infiltrates, but may be normal 
in patients with biopsy proven DPLD. HRCT shows pleural irregularities, ground glass 
attenuation and patchy consolidation38. The frequency of radiographic parenchymal 
abnormalities is low (about 5%). The most common is a symmetric, predominantly basal 
reticular pattern  that may become diffuse over time and progress to honeycombing 36. 
Bilateral areas of consolidation develop in some patients over a 2- to 3-week period. 
HRCT FINDINGS  
The HRCT findings  are prominent interlobular septa, ground-glass attenuation, 
patchy consolidation, parenchymal bands, irregular peribronchovascular thickening, and 
sub pleural lines. Honeycombing may be seen in up to 16% of patients who have 
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abnormal chest radiographic findings or pulmonary function tests39.Patchy consolidation, 
parenchymal bands, and irregular peribronchovascular thickening are seen to improve at 
sequential CT, becoming pleural irregularities, prominent interlobular septa, ground-glass 
attenuation, and sub pleural lines on follow-up CT scans. Therefore, consolidation with 
patchy and sub pleural distribution, parenchymal bands, and irregular 
peribronchovascular thickening are reversible. On occasion, areas of ground-glass 
attenuation with parenchymal bands or sub pleural lines that represent a pathologic area 
of usual interstitial pneumonia may progress to honeycombing. 
SPIROMETRY & DLCO IN PM/DM 
These patients usually have evidence of a restrictive ventilatory pattern with 
reductions in VC and TLC. In addition, the DLCO may also be reduced. The profound 
respiratory muscle weakness, which may often complicate these patient’s courses, may 
be demonstrated by a decrease in maximal inspiratory pressure, maximal inspiratory flow 
rate  and maximal voluntary ventilation. Many patients have resting arterial hypoxemia, 
which is made worse with exercise. Clinical exercise testing is of importance in PM/DM 
patients  to elucidate the cause of dyspnoea, which may not be limited to DPLD, but 
might be due in part to pulmonary hypertension, cardiac dysfunction or muscle 
weakness40. 
SJOGREN’S SYNDROME 
 Sjogren’s syndrome, or the sicca complex, is an autoimmune exocrinopathy 
characterized by lymphocytic infiltration of glandular and extra glandular organs. A 
clinical triad of dry eyes (keratoconjunctivitis sicca), dry mouth (xerostomia), and 
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arthritis characterizes Sjogren’s syndrome. It is relatively common, affecting 0.1% of the 
general population and 3% of older adults 41. It may be primary without features of other 
collagen vascular disease, or secondary in association with other collagen vascular 
disease  most often rheumatoid arthritis. 
Pulmonary manifestations occur frequently in Sjogren’s syndrome. Diffuse 
parenchymal lung disease is probably the most common functional abnormality identified 
in patients with primary Sjogren’s syndrome with lung involvement. The aetiology of 
DPLD associated with Sjogren’s syndrome is unknown, and it appears that lymphocytic 
pneumonitis represents only one pole of the spectrum of diseases, which includes pseudo 
lymphomas and malignant lymphomas. DPLD occur more often in patients with extra 
glandular manifestations than in those with glandular disease alone. 
The most common thoracic complication, lymphocytic interstitial pneumonia  is 
followed in frequency by airway abnormalities such as follicular bronchitis, 
bronchiectasis, and bronchiolitis. Less common complications include interstitial 
pneumonitis and fibrosis, BOOP, lymphoma, pulmonary hypertension, and pleural 
effusion or fibrosis. A large series of 343 patients reported by STRIMLAN 42 clearly 
demonstrated that many patients do not manifest as a single type of pulmonary lesion.  
RADIOLOGIC MANIFESTATIONS 
Parenchymal abnormalities are evident at chest radiography in 10%–30% of 
patients. The most common finding, a reticulonodular pattern that involves mainly the 
lower lung zones, may reflect the presence of lymphocytic interstitial pneumonia or 
interstitial fibrosis. In patients with interstitial opacities on their chest radiograph, a 
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restrictive pattern with a low diffusion capacity is commonly found on lung function 
tests.  
HRCT FINDINGS 
 In Franquet et al study  of high-resolution CT findings among 50 patients 
with Sjogren's syndrome showed the major abnormalities of bronchiectasis, bronchiolar 
inflammation and increased parenchymal line43.There is an increased prevalence of 
lymphocytic interstitial pneumonitis that is seen radiographically as a reticulonodular 
pattern predominantly involving the lower lobes.  
A recent article described the high-resolution CT findings of lymphocytic 
interstitial pneumonia44, with the most common findings being areas of ground glass 
attenuation, thickening of bronchovascular bundles with interlobular septa and cysts. 
DPLD and bronchiolar inflammatory changes are common abnormal findings seen on 
HRCT scans in primary Sjogren’s syndrome. For example, 20% of patients with primary 
Sjogren’s syndrome undergoing HRCT had bronchial wall thickening with either ground-
glass opacification or a small nodular pattern in the majority of these cases. 
SPIROMETRY & DLCO IN SJOGREN’S SYNDROME 
Bariffi and colleagues studied 18 female non-smokers with Sjogren’s syndrome. 
They found that 13 of the 18 had an FEV1/FVC ratio of less than 80% and 7 of 18 had 
anFEV1 of less than 80%, whereas 9 of 14 had a maximum flow at 25% of VC (MEF25) 
of less than 80%45 .In addition, these investigators found abnormalities in diffusing 
capacity. Constantopoulos and colleagues, in a study of 61 patients with primary 
Sjogren’s syndrome, at least 50% of patients had a decline in either MEF25 or MEF50, 
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whereas only 10% had a low FEV146. However, other investigators performed a 
longitudinal study of 18 asymptomatic, non-smoking women with normal chest 
radiographs. In this group, baseline FEV1/FVC, FVC, and TLC were normal in all 
patients. Only 17% had a diffusion defect.  
When compared with secondary Sjogren’s syndrome, there was a higher 
incidence of restrictive pattern in primary Sjogren’s syndrome whereas an obstructive 
ventilator defect was more common in secondary Sjogren’s syndrome or RA alone. The 
significance of diffusion defects in patients with primary Sjogren’s syndrome remains of 
uncertain significance; in a 10-year follow-up of pulmonary involvement in 30 patients, a 
significant decline in diffusion was seen at 4 years followed by a significant improvement 
at 10 years, in the absence of any intervention. 
MIXED CONNECTIVE TISSUE DISEASE (MCTD) 
The term mixed connective tissue disease refers to a condition in which patients 
have mixed features of systemic lupus erythematosus, progressive systemic sclerosis, and 
polymyositis. There is an 8:1female to male ratio and no racial predilection. Suggested 
clinical criteria for the diagnosis are 1) Positive for anti RNP plus 2) Three or more 
clinical features such as Hand oedema, Synovitis, Myositis, Raynaud’s phenomenon and 
Acrosclerosis. After several years, MCTD may transform into one of the classic disease. 
Pulmonary involvement has been described in 20–85% of patients with mixed 
connective tissue disease (MCTD)47. Common pulmonary abnormalities include 
interstitial pneumonitis with fibrosis, pulmonary hypertension and pleural effusion. 
Clinical features of DPLD associated with MCTD are similar to those reported in 
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scleroderma and consist of Idiopathic Pulmonary Fibrosis with alveolar inflammatory 
processes and progressive development of honeycomb formation; generally, the degree of 
fibrosis appeared more severe in patients exhibiting scleroderma feature. 
Radiologic manifestations 
 One-third of patients with mixed connective tissue disease had initial chest 
roentgenograms that were abnormal demonstrating small irregular opacities involving the 
lung base.  
HRCT FINDINGS  
In HRCT Pulmonary involvement in mixed connective tissue disease has been 
characterized as the presence of ground-glass attenuation, nonseptal linear opacities, with 
a peripheral and lower-lobe predominance. The frequency of pulmonary abnormalities 
varies considerably in different series. In a review of the CT  findings  in 41 patients with 
MCTD, Kozuka et al found ground glass, sub pleural micro nodules, non-septal linear 
and reticular abnormality  in more than 50% of cases.  
In a retrospective study of 81 patients at the Mayo Clinic48, an interstitial pattern 
was seen at chest radiography in 19%; on the other hand, careful prospective study of 34 
patients in another investigation showed interstitial abnormalities in 85%. The 
abnormalities consist of irregular linear hyper attenuating areas with a reticular pattern 
and involving mainly the lung bases. With the progression of disease, the fibrosis 
gradually extends superiorly; in the late stage, honeycombing may be identified. High 
resolution CT shows a predominant sub pleural distribution of fibrosis. Other radiological 
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abnormalities include areas of parenchymal consolidation that may be related to 
Bronchiolitis Obliterans Organising Pneumonia. 
SPIROMETRY & DLCO IN MCTD 
Pulmonary function abnormalities include a reduction of the DLCO, a decreased 
VC, TLC, and FEV1.Abnormal PFT and chest radiographs are frequent. Impaired DLCO 
has been reported in 67%, and restrictive lung volumes in 50% of MCTD. DLCO appears 
to be the most sensitive single parameter in evaluating pulmonary dysfunction in MCTD. 
RADIOLOGIC IMAGING IN DPLD 
Patients with suspected DPLD will have a chest radiograph as the initial imaging 
investigation. In most cases, this is abnormal and occasionally the radiographic 
appearances are sufficiently characteristic to enable a specific diagnosis to be made when 
taken in conjunction with the clinical and laboratory findings. Chest radiograph  is an 
essential test for the assessment of DPLD, however a normal Chest Radiograph cannot 
exclude the diagnosis. If available, previous x-rays or reports of x-rays should be 
obtained and compared with the recent x-rays. In appropriate clinical settings, HRCT 
may be sufficiently characteristic to preclude the need for biopsy7. 
PULMONARY HRCT 
 HRCT scanning is capable of imaging the lung  with excellent spatial resolution 
and providing anatomical detail similar to that seen by gross pathological examination. 
Images are usually obtained in the supine and prone position. In normal patients, 
dependent lung opacity is often seen in the posterior, subpleural regions of the lung. In 
certain diffuse lung diseases, such as nonspecific interstitial pneumonia (NSIP), images 
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can be identical to those seen in normal patients. Prone images will differentiate between 
these two possibilities, since normal dependent density in the posterior lung will 
disappear on prone images, whereas true lung disease-related density will persist. 
Dynamic expiratory images are also obtained to screen for air trapping. 
1.Detection of DPLD 
HRCT scanning is able to detect DPLD not visible on the chest radiograph. The 
relative sensitivities of the two techniques for the detection of DPLD are 94% and 80%, 
respectively.              
2.Characterisation of disease and extent of disease   
  The diagnostic accuracy of HRCT scanning is further increased by concurrent 
clinical evaluation49.Unlike chest radiography, HRCT scans provide cross sectional 
images and the extent of disease is therefore much more readily appreciated than on the 
chest radiograph. HRCT scanning may also elucidate patients with complex lung function 
abnormalities—for example, co-existing fibrosing  alveolitis and emphysema.    
3.Impact on lung biopsy samples   
HRCT scanning has a high degree of accuracy in many forms of DPLD. The 
percentage of first choice diagnoses made with a high level of confidence in two studies 
was 82% and 93%.Fibrosing alveolitis may be confidently distinguished from other 
forms of DPLD with an accuracy of 88%. Using Bayesian analysis, Grenier et al 
concluded that the combination of clinical, radiographic, and HRCT findings enabled a 
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correct diagnosis with a high level of confidence in 61–80% of patients with DPLD. 
Based on the findings it is evident that HRCT scanning can prevent the need for a 
histological diagnosis.   For patients in whom lung biopsy samples are required, HRCT 
scanning is better able to differentiate between the need for transbronchial biopsy or open 
lung biopsy samples. It is also able to determine the most appropriate areas from which 
the biopsy samples should be taken. 
4.Assessment of disease activity  
There is evidence that a predominant ground glass pattern and is more likely to 
represent active inflammatory disease and to respond to appropriate therapy  Reticular 
and honeycomb patterns on HRCT scans correlate well with histological evidence of 
fibrosis.    
5.Prediction of response to treatment  
Because of its ability to differentiate between cellular and fibrotic disease with 
reasonable accuracy, HRCT scanning can be used to predict response to treatment and is 
significantly more accurate than chest radiography in this respect.  
HRCT PATTERNS50 
1. Reticular opacities: Thickening of the interstitial connective tissue network of 
the lung will result in reticular opacities of varying morphology. This thickening can 
result from fluid/cellular infiltration or deposition of fibrous tissue. 
 26
2. Nodules: There are several ways to classify nodules: well defined vs. poorly 
defined; upper vs. lower lobe distribution; and relationship to the secondary pulmonary 
lobule. The last is the most useful characteristic, since it provides a focused differential 
diagnosis and is reflective of the underlying disease pathophysiology. There are three 
possible HRCT distributions of nodules: perilymphatic, random, and centrilobular. 
3. Honeycombing: Honeycomb lung remodelling (honeycombing) reflects the end 
stage of a number of diseases that cause parenchymal destruction. It presents a 
characteristic HRCT pattern, with subpleural, thick-walled cysts that share walls and, 
when advanced, are often stacked in multiple layers. Other signs of fibrosis (traction 
bronchiectasis and reticulation) typically accompany it. Honeycombing is highly 
suggestive of a pathologic diagnosis of usual interstitial pneumonia (UIP), although it can 
be attributable to other diseases 
4. Traction bronchiectasis: Bronchial dilatation occurring as a consequence of 
interstitial fibrosis is referred to as traction bronchiectasis.The bronchi often appear 
irregular (corkscrewed) and are not associated with radiologic evidence of bronchial 
inflammation (gross bronchial wall thickening or mucous impaction). Other signs of lung 
fibrosis (honeycombing or irregular reticulation) often accompany traction 
bronchiectasis. While traction bronchiectasis is quite specific for fibrosis, the differential 
diagnosis is broader than that of honeycombing.  In patients with known collagen 
vascular disease, bibasilar, peripheral, traction bronchiectasis accompanied by ground-
glass attenuation can be considered diagnostic of NSIP. 
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5. Ground glass opacity:GGO  is increased lung opacity that does not obscure the 
associated vessels and represents abnormalities below the resolution of HRCT. GGO has 
been associated with active or reversible lung disease. However, ground-glass opacity 
can also be seen in cases in which fibrosis is the predominant abnormality. Ground-glass 
attenuation can only be considered as reflecting the presence of potentially reversible 
disease if there are no associated findings of fibrosis in the same area. The differential 
diagnosis of ground glass opacity should be based upon the host immune status and 
duration of symptoms. The presence of connective tissue diseases, environmental 
inhalants, and drug use also should be considered when increased diffuse lung opacity is 
present. 
Pulmonary Function Tests 
Full pulmonary function tests (PFT) should be performed in all cases of suspected 
DPLD. They aid in the diagnosis, assessment of disease severity, response to treatment 
and prognosis. PFT measurements should include forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), FEV1/FVC ratio, vital capacity (VC) and diffusion 
capacity of carbon monoxide (DLCO). 
Lung function tests are usually restrictive with small lung volumes seen as 
reduced VC in DPLD. The FEV1/FVC ratio is either maintained or often increased. 
DLCO is typically reduced in DPLD to greater extent than the lung volumes. Coexistence 
of DPLD with obstructive airway disease (e.g. emphysema), can confuse the results with 
a mixed pattern of restriction observed as reduced lung volumes and obstruction 
manifesting as a reduced FEV1/FVC ratio. DPLD are usually thought to be characterised 
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by restrictive lung function, by which is meant a reduction in lung volumes with 
preserved ratio of forced expiratory volume in one second. 
Diagnosis and assessment of diffuse parenchymal lung disease can be done with 
FEV1, forced vital capacity (FVC),  FEV1/FVC ratio, and  VC   together  with a reduction 
in  carbon monoxide  transfer  factor (DLCO). However, in early disease lung volumes 
and transfer factor may be within the normal range. In systemic sclerosis, an isolated 
reduction in DLCO may point to pulmonary vascular disease. In one study, 19% of PSS 
patients had such abnormal lung function, 11% of whom developed isolated pulmonary 
hypertension and the risk increasing markedly with lower DLCO. Patients may often be 
too ill to perform the tests and the investigations lack the appropriate sensitivity and 
specificity to be of diagnostic value.  
Lung function tests are conventionally used to give a global index of functional 
impairment. Vital capacity (VC), total lung capacity (TLC), and DLCO are most 
commonly used while in the UK, exercise testing is used relatively little. Several studies 
have correlated lung function and exercise test parameters with the degree of pathological 
abnormality on lung biopsy samples using the latter as the gold standard. Watters et al 
developed a composite clinical radiographic physiological (CRP) score using seven 
variables: dyspnoea, chest radiograph, FEV1 and FVC, TLC, DLCO/VA, resting A–a 
gradient, and exercise oxygen saturation.  
 29
ATS RECOMMENDATION FOR PERFORMING DLCO51 
Equipment 
1. Volume accuracy same as for spirometry(±3% over 8L range, all gases) 
2. Documented analyzer linearity from 0 to full span ± 1% 
3. Circuit resistance less than 1.5cm H2 O at 6 L/sec flow 
4. Demand valve sensitivity less than 10 cm H2O to generate 6L/sec flow 
5. Timing mechanism accurate to ±1% over 10 sec; checked quarterly 
6. Documented instrument dead space(Inspiratory/Expiratory) less than 0.1L 
7. Check for leaks and volume accuracy(3L calibration) daily 
8. Validate system by testing healthy non smokers ( Biologic control ) quarterly 
Technique 
1. Subject should refrain from smoking for 24 hours before the test 
2. Subject should be instructed carefully before the procedure 
3. Subject should inspire rapidly;2.5 sec or less for healthy subjects, 4 sec or less in 
obstruction 
4. Subject should achieve an inspired volume greater than 90% of VC 
5. Subject should achieve breath hold for 9-11 sec, relaxing against closed glottis or 
closed valve ( No valsalva or mullers manoeuvre ) 
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6. VD  wash out should be 0.75 L-1.0L(0.5 L if VC less than 2.0 L) 
7. Alveolar sample volume should be 0.5-1.0 L collected in less than 4 sec 
8. Visual inspection of  VD  washout and alveolar sampling should be used for 
system that continuously analyzes expired gas 
9. Test gas should contain 21% O2 at sea level; supplemented O2 should be 
discontinued before testing if possible 
10. Four minutes should elapse between repeat tests 
Calculations 
1. Average at least two acceptable tests; duplicate determinations should be within 
10% or 3ml/min/mm of Hg  
2. Use Jones method of timing of breath hold 
3. Alveolar volume should be determined by single breath dilution of tracer gas 
4. Adjust for VD volumes (Instrument and patient ) 
5. Determine  inspired gas conditions( ATPS or ATPD ) 
6. Correct for CO2 and H2O absorption 
7. Report DL/VA in ml CO ( STPD )/min/mm Hg per L( BTPS ) 
8. Correct for Haemoglobin concentration 
9. Adjust for COHb 
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10. Adjust for altitude 
11. Use reference equations appropriate to the laboratory method and patient 
population  
Acceptable test criteria for diffusing capacity of the lung for carbon monoxide 
Use of proper quality-controlled equipment, 
VI  (Inspired Volume) of >85% of largest VC in <4 sec, 
A stable calculated breath hold for 10±2 s. There should be no evidence of leaks, or 
 Valsalva or Mueller maneuvers, 
Expiration in <4 s (and sample collection time <3 s), with appropriate clearance of VD 
 (Dead  space volume) and proper sampling/analysis of alveolar gas. 
Pulmonary Function Tests in DPLD52 
1. Severity and pattern of disease 
Simple lung function testing using lung volumes and gas transfer factor gives a 
reasonable measure of the extent of disease. 
2. Monitoring the course of the disease 
VC and DLCO are the most appropriate and simplest indicators of change in 
DPLD. DLCO  predict survival in some studies. In Wells et al20 study, increased 
mortality is associated with reduced DLCO, FVC and TLC. The one index that 
appears to be a good predictor of the subsequent clinical course is DLCO.   
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IV.  MATERIALS AND METHODS 
This prospective study was organized in the Institute of Thoracic medicine and 
department of Thoracic medicine, Government General Hospital in association with 
department of Rheumatology, Government General Hospital. Subjects were recruited 
from the Pulmonary and Rheumatology outpatient clinic of our hospital. This study was 
approved by  the  ethical committee of this institution. 
The design of the work is a prospective study. The study extended from the period 
of January 2008 to November 2008 and it was performed at the  Institute of Thoracic 
medicine with the same population referred from the department of Rheumatology, 
Government General Hospital, Chennai. 
INCLUSION CRITERIA 
1. Clinically and radiologically confirmed cases of  DPLD. 
2. Age > 12 years. 
3. Sex- Both genders. 
4. Patients who are able to perform spirometry and diffusion capacity with a 
breath holding period of  at least 10 seconds. 
5. Serologically positive collagen vascular disease patients. 
EXCLUSION CRITERIA 
1. Patient associated with history  suggestive of  Infection, Allergy and 
immunosuppression. 
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2. Patient associated with any other respiratory disease, cardiovascular 
disease,  and malignancy. 
3  Smokers are virtually eliminated from the study as a confounding factor  
(For example respiratory bronchiolitis of smoking can be falsely attributed 
to collagen vascular disease). 
4. DPLD due to other  causes or of unknown aetiology. 
5. Breath-holding time <9 or >11 seconds, or with an inspiratory capacity 
less than 85% of the largest previously measured vital capacity. 
METHODOLOGY 
In essence, without proper medical history all Diffuse parenchymal lung diseases 
are of unknown cause. For an accurate diagnosis, there is no substitute for complete 
clinical evaluation. This should be considered  as the  key diagnostic steps in the 
evaluation of patient who has DPLD. 
Thorough history elicitation with comprehensive evaluation of the chief 
complaint and comprehensive review of  multiple systems were done.  
  Medical history was taken with special reference to previous cardiopulmonary 
disease, cough, exertional dyspnoea, sputum, chest pain and risk factors for pulmonary 
disease, such as smoking.  
Then followed by exhaustive review of past medical, social, family and 
occupational histories with an exploration of all potential environmental exposures were 
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done. The clues that surface during this evaluation help to narrow the broad differential 
diagnosis to few possible disorders as per ATS recommendation. 
PULMONARY HRCT  
 The patients were then subjected to the High-resolution computed tomography 
(HRCT) in the   supine  position,  holding  breath at deep inspiration,  without contrast 
medium. Prone sections were taken when posterior images obtained on supine sections 
were suspected of having artefacts due to gravity dependent perfusion. The added value 
of HRCT scanning in DPLD depends upon its ability to increase confidence of a specific 
diagnosis by characterisation and profusion of lesion on representative anatomical level, 
to alter  patient management and if possible, to influence the outcome49. (Fig A, B, C 
&D). 
Pulmonary Function Tests 
 After completing the physical examination  and HRCT of those who have fulfilled 
criteria, were subjected to  pulmonary function test. The various manoeuvres of PFT were 
explained and practically demonstrated to them. 
 PFT was deferred to those persons who were suspected of having respiratory tract 
infection. A course of antibiotics were given to them and asked to come for the next 
session for the completion of  PFT.  
ATS RECOMMENDATION FOR PERFORMING SPIROMETRY51 
Procedures for recording spirometry were done as per ATS recommendation that 
include; Checking the spirometer calibration, Explanation of the test to subject, 
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Preparation of the subject including asking about smoking, recent illness, medication use, 
etc.and measurement of weight and height without shoes. The subject  were then 
instructed and demonstrated about  the test  including correct posture with head slightly 
elevated, rapid and complete inhalation and exhalation with maximal force. 
After assuming the correct posture nose clip was attached and mouthpiece was 
placed in mouth with close lips around the mouthpiece. Patient was instructed to inhale 
completely and rapidly with a pause of one second at Total Lung Capacity and then to 
exhale maximally until no more air can be expelled while maintaining an upright posture. 
Repeated instructions were given. Minimum of three manoeuvres were repeated; no more 
than eight are usually required.  
The variables recorded included FVC, FEV1 and FEV1 /FVC ratio. Three 
technically satisfactory measurements were obtained in which FVC was reproducible 
within 300 ml. The subject’s FVC was defined as the maximal FVC which was 
determined before the DLCO test, as recommended by the ATS. 
ATS RECOMMENDATION FOR PERFORMING DLCO53 
DLCO measurements were performed in compliance with the American Thoracic 
Society (ATS) guidelines. DLCO was measured using a single-breath technique. The 
DLCO was routinely adjusted for haemoglobin if the value was outside the normal range. 
Measurements of DLCO were made with a Collins automated system using a gas mixture 
that contained 0.3% Methane tracer gas and 0.3% carbon monoxide. The breath holding 
time was 10 seconds and the washout volume was 0.75 L. Each subject’s height and 
weight were measured.  
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The participants were seated, wearing nose clips, and performed at least two 
DLCO manoeuvers separated by more than 4 minutes.  The mean DLCO value from two 
manoeuvers that matched within 3 ml/min/mm Hg was reported.  
Before the test was performed, each subject was instructed about all of the 
required manoeuvers. After the subject had adapted to the mouthpiece of the test 
apparatus, four or five tidal volumes were recorded to determine a regular end expiratory 
baseline. The subject was then asked to exhale as far as possible, to the point till maximal 
exhalation had been reached (residual volume RV); making a rapid, maximal inhalation 
within 2 to 2.5 seconds to VC continuing to hold the breath for 10 seconds while relaxing 
against a closed glottis and exhaling rapidly. If after two attempts an acceptable 
measurement could not be made, the procedure was then abandoned. 
The values were interpreted as follows:  
DLCO and DLCOHb : Normal(>80% predicted)  Mild diffusion defect (65-80%), 
Moderate diffusion defect(45-65%) and severe diffusion defect(<45%).          
FVC:Normal(>80% predicted), Mild Reduction(60-80%), Moderate 
Reduction(40-60%), Severe Reduction(<40%). 
Statistical analysis 
 The following statistical analyses were performed to assess the strength of 
association between the variables of the study by using Chi-Square  Test . HRCT pattern 
and  DLCO in DPLD groups were compared by Mantel-Haenszel test  for linear 
association and a p value of  <0.05 was considered significant. 
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V. RESULTS 
 In our study 55 patients were screened for Diffuse Parenchymal Lung Diseases 
with collagen vascular diseases. Out of which 36 patients were taken up for the study 
after satisfying eligible criteria. All were nonsmokers. Remaining patients were excluded 
from the study group based on exclusion criteria. 
AGE 
 In our study population age group ranges from 16-74 years. 
Age Group ( Years ) No of Patients Percentage (%)
<35  
36-45 
46-55 
>55 
9 
11 
7 
9 
 
25 
30.56 
19.44 
25 
 
TOTAL 36 100 
 
 Maximum number of patients present presented between the ages of 36-45 years. 
The mean age distribution found in our study is 44. The calculated standard deviation is 
13.79.Hence 95% of confidence interval lies in the range of 44± 4.5 , indicating that most 
of them fall in late fourth decade. 
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SEX 
 
 
 
 
 
The selected patients consisted of 66.67% Females and 33.33% males. 
Male: Female sex ratio  is 1:2 (Fig 2). 
Disease classification 
 
 
 
 
 
 
 
 
 
SEX No of Patients Percentage (%) 
Male 
Female 
12 
24 
33.33 
66.67 
Total 36 100 
Disease No of patients Percentage (%) 
Systemic Sclerosis 
Rheumatoid Arthritis 
Mixed Connective Tissue Disease 
Systemic Lupus Erythematosus 
Polymyositis/Dermatomyositis 
Sjogren’s syndrome 
16 
12 
3 
2 
2 
1 
44.44 
33.33 
8.33 
5.56 
5.56 
2.78 
Total 36 100 
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Clinical Features 
 
 
 
 
 
Rheumatoid arthritis and Systemic sclerosis form the bulk of the study population. 
Both constitute more than 75% of the cases. Followed by three cases of MCTD and two 
cases each from SLE and PM/DM and one case of Sjogren’s syndrome. (Fig 3). 
The  predominant symptom found in majority of the study cases  are  Exertional 
dyspnoea(88.89%),  followed  by  cough(50%)  and chest pain(25%).  Bibasilar crackles 
heard in 16(55.56%) cases out of 36 cases. 
 Extra pulmonary symptoms are Dyspepsia, Dyphagia, Raynaud's phenomenon, 
inflammatory arthritis, subcutaneous nodules, Sicca syndrome, Skin changes like rash, 
discolouration and thickening, proximal muscle weakness, etc . These above-mentioned 
symptoms present concomitantly in our cases and these symptoms have preceded or 
accompany with respiratory illness. 
 
No of Patients Clinical Features 
Present(%) Absent(%) 
Exertional Dyspnoea 
Cough 
Chest pain  
Bibasilar crackles 
32(88.89%) 
18(50%) 
9(25%) 
16(44.44) 
4(11.11%) 
18(50%) 
27(75%) 
20(55.56) 
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HRCT patterns 
HRCT patterns No of patients Percentage (%) 
RN 
GGO  
RGN 
RGHT 
RH 
RGH 
14 
 7 
 6 
 5 
 3 
 1 
38.9 
19.5 
16.6 
13.9 
 8.3 
 2.8 
Total 36 100 
R-Reticular,G-Ground glass ,H-Honey combing,T-Traction bronchiectasis, N-Nodular 
In our study population various combinations of Reticular, Ground glass opacity, 
Honey combing, Traction bronchiectasis, and Nodular patterns were seen. Of which 
ReticuloNodular pattern forms the most common presentation(38.9%).Followed by 
Ground glass opacity(19.5%),RGN(16.6%)and RGHT(13.9%) . Less common being 
RH(8.3%) and RGN(2.8%) (Fig 4). 
Individual patterns in HRCT 
 
 
 
 
 
HRCT pattern No of patients Percentage (%) 
Reticular 
Nodular 
Ground glass opacity 
Honeycombing 
Traction 
bronchiectasis 
29 
21 
18 
8 
5 
 
80.6 
58.3 
50 
22.2 
13.9 
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Reticular pattern  is the most frequent presentation (80.6%) followed by Nodular 
pattern (58.3%) and GGO pattern(50%). Less common are Honeycombing  and Traction 
bronchiectasis(22.2% and 13.9% respectively) (Fig 5).  
Spirometry 
Forced Vital capacity(FVC) No patients Percentage(%) 
Normal 
Mild restriction 
Moderate restriction 
Severe restriction 
8 
6 
18 
4 
22.22 
16.67 
50 
11.11 
Total 36 100 
 
  Out of 36 cases of study population 28 cases were presented with restriction 
pattern (>75%) and remaining eight  were presented with Normal FVC(22.22%). Forced 
vital capacity suggestive of Moderate restriction constitutes 50% of study population 
followed by  Normal FVC(22.22%), Mild restriction(16.67%) and Severe restriction 
(11.11%) in decreasing frequency(Fig 6). 
Diffusing capacity 
DLCO DLCO Hb Diffusing capacity 
No  (%) No (%) 
Normal 
Mildly reduced diffusing capacity 
Moderately reduced diffusing capacity 
Severely   reduced diffusing capacity 
5 
5 
7 
19 
13.89 
13.89 
19.44 
52.78 
5 
7 
6 
18 
13.89 
19.44 
16.67 
50 
Total 36 100 36 100 
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In DLCO Severely reduced diffusing capacity(52.78%) is the most common 
presentation in study population followed by moderately reduced diffusing capacity and 
then by equal presentations of  Normal  diffusing capacity and mildly reduced diffusing 
capacity(13.89% each).  
In DLCO for corrected Haemoglobin Severely reduced diffusing capacity(50%)  
is the most common presentation in study population. Followed by mildly reduced 
diffusing capacity(19.44%), moderately reduced diffusing capacity(16.67%) and Normal  
diffusing capacity(13.89%). (Fig 7). 
FVC Vs DLCO 
Normal Mild Moderate Severe Total FVC 
No % No % No % No % No 
Normal 3 37.5 3 37.5 2 25 - - 8 
Mild 1 16.7 1 16.7 1 16.7 3 49.9 6 
Moderate 1 5.6 1 5.6 4 22.1 12 66.7 18 
Severe - - - - - - 4 100 4 
 
FVC Vs DLCOHb 
Normal Mild Moderate Severe Total FVC 
No % No % No % No % No 
Normal 3 37.5 5 62.5 - - - - 8 
Mild 1 16.7 1 16.7 1 16.7 3 49.9 6 
Moderate 1 5.6 1 5.6 5 27.7 11 61.1 18 
Severe - - - - - - 4 100 4 
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In both DLCO and DLCOHb Severly reducing diffusing capacity is associated 
with severe reduction in FVC in all 4 cases(100%). Out of five normal DLCO and 
DLCOHb patients two patients exhibit reduction in FVC (Fig 8). 
HRCT Vs DLCO 
Normal Mild Moderate Severe Total  
HRCT patterns 
No % No % No % No % No 
RN 
Reticulo Nodular 
 
2 14.3 3 21.4 3 21.4 6 42.9 14 
GGO 
Ground Glass Opacity 
 
2 28.6 2 28.6 3 42.8 - - 7 
RNG 
Reticulo Nodular with 
Ground Glass Opacity 
1 16.7 - - 1 16.7 4 66.6 6 
RGHT 
Reticular, Ground  glass 
opacity,  Honeycombing 
&Traction bronchiectasis 
- - - - - - 5 100 5 
RH 
Reticular & 
Honeycombing 
- - - - - - 3 100 3 
RGH 
Reticular, Ground  glass 
opacity& Honeycombing 
- - - - - - 1 100 1 
The various presentations of HRCT patterns in each individual  were correlated 
with Diffusing capacity(DLCO). Out of 14 cases of RN(ReticuloNodular) pattern 6 
cases(42.9%) were present in severely reduced diffusing capacity followed by 3 
cases(21.4%) each in mild and moderately reduced diffusing capacity, then 2 
cases(14.3%) in normal diffusing capacity. 
Out of 7 cases of GGO(Ground Glass Opacity) 3 cases(42.8%) were present in 
moderately reduced diffusing capacity followed by 2 cases(28.6%) each in normal and 
mildly reduced diffusing capacity. 
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Out of 6 cases of RGN (Reticular, Ground glass opacity, Nodular) pattern 4 
cases(66.6%) were present in severely reduced diffusing capacity followed by one case 
(16.7%) each in Normal diffusing capacity and moderately reduced diffusing capacity. 
All 5 cases(100%) of RGHT (Reticular, Ground glass opacity, Honeycombing 
and Traction bronchiectasis) pattern present only in severely reduced diffusing capacity. 
Out of 3 cases of RH (Reticular, Honeycombing) pattern all (100%)  were present 
in severely reduced diffusing capacity. 
1 case(100%) of RGH (Reticular, Ground glass opacity, Honeycombing) pattern 
was present in severely reduced diffusing capacity (Fig9).  
HRCT Vs DLCOHb 
Normal Mild Moderate Severe Total  
HRCT patterns 
No % No % No % No % No 
RN 
Reticulo Nodular 
 
2 14.3 3 21.4 3 21.4 6 42.9 14 
GGO 
Ground Glass Opacity 
 
2 28.6 4 57.1 1 16.7 - - 7 
RNG 
Reticulo Nodular with 
Ground Glass Opacity 
1 16.7 - - 1 16.7 4 66.6 6 
RGHT 
Reticular, Ground  glass 
opacity,  Honeycombing 
&Traction bronchiectasis 
- - - - - - 5 100 5 
RH 
Reticular & 
Honeycombing 
- - - - 1 33.3 2 66.7 3 
RGH 
Reticular, Ground  glass 
opacity& Honeycombing 
- - - - - - 1 100 1 
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The various presentations of HRCT pattern in each individual  is correlated with 
Diffusing capacity for corrected Haemoglobin(DLCOHb).  
Out of 14 cases of RN(ReticuloNodular) pattern 6 cases(42.9%) were present in 
severely reduced diffusing capacity followed by 3 cases(21.4%) each in Mild and 
moderately reduced diffusing capacity, then 2 cases(14.3%) in Normal diffusing capacity. 
Out of 7 cases of GGO(Ground Glass Opacity) 4 cases(57.1%) were present in 
mildly reduced diffusing capacity followed by 2 cases(28.6%) in Normal and 1 case 
(14.3%) in moderately reduced diffusing capacity. 
Out of 6 cases of RGN (Reticular, Ground glass opacity, Nodular) pattern 4 
cases(66.6%) were present in severely reduced diffusing capacity followed by one case 
(16.7%) each in Normal diffusing capacity and moderately reduced diffusing capacity. 
All 5 cases(100%) of RGHT (Reticular, Ground glass opacity, Honeycombing 
and Traction bronchiectasis) pattern present only in severely reduced diffusing capacity. 
Out of 3 cases of RH (Reticular, Honeycombing) pattern 2 cases (66.7%)  were 
present in severely reduced diffusing capacity followed by 1 case in(33.3%) moderately 
reduced diffusing capacity . 
1 case(100%) of RGH (Reticular, Ground glass opacity, Honeycombing) pattern 
was present in severely reduced diffusing capacity (Fig10).  
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INDIVIDUAL HRCT PATTERN Vs DLCO 
Normal Mild Moderate Severe Individual HRCT 
pattern 
No % No % No % No % 
Total 
Reticular 3 10.3 3 10.3 4 13.8 19 65.6 29 
Nodular 3 14.3 3 14.3 4 19 11 52.4 21 
GGO 3 16.7 2 11.1 3 16.7 10 55.6 18 
Honeycombing - - - - - - 8 100 8 
Traction 
Bronchiectasis 
- - - - - - 5 100 5 
 
Out of 29 cases of Reticular pattern 19 cases(65.6%) were present in  Severely 
reduced diffusing capacity followed by 4 cases(13.8%) in moderately reduced diffusing 
capacity and 3 cases(10.3%) each in normal diffusing capacity and mildly reduced 
diffusing capacity. 
Out of 21 cases of Nodular pattern 11 cases(52.4%) were present in  Severely 
reduced diffusing capacity followed by 4 cases(19%) in moderately reduced diffusing 
capacity and 3 cases(14.3%) each in normal diffusing capacity and mildly reduced 
diffusing capacity. 
Out of 18 cases of GGO pattern 10 cases(55.6%) were present in  Severely 
reduced diffusing capacity followed by 3 cases(16.7%) each in moderately reduced 
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diffusing capacity and  normal diffusing capacity  and 2 cases(11.1%) in mildly reduced 
diffusing capacity. 
All 8 cases(100%) of Honeycombing pattern 19 cases were present in  Severely 
reduced diffusing capacity. 
All 5 cases(100%) of Traction Bronchiectasis pattern  were present in  Severely 
reduced diffusing capacity (Fig 11). 
INDIVIDUAL HRCT PATTERN Vs DLCOHb 
Normal Mild Moderate Severe Individual HRCT 
pattern 
No % No % No % No % 
Total 
Reticular 3 10.3 3 10.3 5 17.2 18 62.2 29 
Nodular 3 14.3 3 14.3 4 19 11 52.4 21 
GGO 3 16.7 3 16.7 2 11.1 10 55.6 18 
Honeycombing - - - - 1 12.5 7 87.5 8 
Traction 
Bronchiectasis 
- - - - - - 5 100 5 
 
Out of 29 cases of Reticular pattern 18 cases(62.2%) were present in  Severely 
reduced diffusing capacity followed by 5 cases(17.2%) in moderately reduced diffusing 
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capacity and 3 cases(10.3%) each in normal diffusing capacity and mildly reduced 
diffusing capacity. 
Out of 21 cases of Nodular pattern 11 cases(52.4%) were present in  Severely 
reduced diffusing capacity followed by 4 cases(19%) in moderately reduced diffusing 
capacity and 3 cases(14.3%) each in normal diffusing capacity and mildly reduced 
diffusing capacity. 
Out of 18 cases of GGO pattern 10 cases(55.6%) were present in  Severely 
reduced diffusing capacity followed by 3 cases(16.7%) each in mildly reduced diffusing 
capacity and  normal diffusing capacity  and 2 cases(11.1%) in moderately reduced 
diffusing capacity. 
Out of 8 cases of Honeycombing pattern 7 cases(87.5%) were present in  Severely 
reduced diffusing capacity and one case(12.5%) in moderately reduced diffusing 
capacity. 
All 5 cases(100%) of Traction Bronchiectasis pattern  were present in  Severely 
reduced diffusing capacity (Fig 11). 
Significant  p value association occurs between the  HRCT patterns  and    
DLCOHb     at   5%  level by using Chi-   Square  Mantel-Haenszel test for linear 
association. 
Significant  p value association occurs between the  HRCT patterns  and    FVC     
at   1%  level by using Chi-   Square  Mantel-Haenszel test for linear association. 
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Significant  p value association occurs between FVC Vs DLCO( p value 0 .0001) 
also FVC Vs  DLCO Hb  (p value 0.003) at 1% level by using Chi-Square  Mantel 
Haenszel test for linear association. 
Reticular Pattern  was the most frequent presentation (80.6%), and has significant 
p value  association with DLCO & DLCO Hb by using Chi-Square Pearson test for linear 
association. 
Significant  p value association occurs between the  Honeycombing pattern  and    
DLCO and DLCOHb  by using Chi-   Square  Pearson test for linear association. 
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VI. DISCUSSION 
Our study principally focuses on characterisation of HRCT pattern of DPLD 
analysed by comparing with Spirometry (Forced Vital Capacity) and Diffusing capacity 
for Carbon monoxide(DLCO) and for Diffusing capacity of Carbon monoxide for 
corrected Haemoglobin(DLCOHb). 
In our study group most of them fell in late fourth decade. Female predominance 
is noted in DPLD with collagen vascular disease patients. 
Rheumatoid arthritis and  Systemic sclerosis  constitute more than 75% of the 
cases. All cases with FVC presented as either restriction or Normal FVC. FVC  presented 
with restriction pattern in >75% of study population. The  predominant symptom found 
in majority of the study cases  are  Exertional dyspnoea pattern (16.67%) 
In HRCT pattern ReticuloNodular pattern forms the most common presentation 
(38.9%) followed by GGO(16.67%).  
When individual HRCT patterns concerned Reticular Pattern was the most 
frequent presentation (80.6%), and had significant association of p value 0.007 with 
severely reducing diffusing capacity(DLCO Hb). 
All patients with RGHT and RGH patterns had severe reduction in DLCO. Severe 
reduction in DLCO was also found in two thirds of patients with RH and RNG, less than 
half of  patients with RN and was rare in patients with GGO. 
In WELLS et al.20 study, DLCO is the best index of the extent of the DPLD when 
compared with HRCT as the "gold standard”.  
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 Warrick et al54 has defined a score based on the criteria of type and extent of 
HRCT signs in systemic sclerosis patients. They found a negative correlation between 
single-breath carbon monoxide lung diffusion capacity (DLCO) and HRCT score. But 
later Diot et al55  found  a  strong   inverse  correlation  between  HRCT score and  DLCO     
(p < 0.0002 )in SS patients.  
We were able to confirm the correlation observed between DLCO and DLCOHb 
and certain HRCT patterns in DPLD with collagen vascular disease patients. 
In Demosthenes Bouros, Athol U. Wells et al57  study in PSS Outcome is linked 
more   strongly to disease severity at presentation and serial DLCO trends than to 
histopathologic findings. The percent predicted DLCO best reflects the extent of 
fibrosing alveolitis in PSS, and therefore should be measured in routine evaluations52. 
In Bodolay et al56 study of MCTD population, reduced DLCO was the most 
sensitive test for predicting the presence of fibrosing alveolitis on HRCT, but the overall 
correlation of pulmonary function with radiographic appearance was poor. 
5 cases of Normal DLCO Hb are associated with 2 cases each of Reticulonodular 
pattern  and GGO pattern and 1 case with RGN(Reticular, Ground glass opacity, 
Nodular) pattern (significant p value <0.05). Out of five normal DLCO and DLCOHb 
patients two patients exhibit reduction in FVC. This is probably explained by correlation 
with age( both are above 60 years). 
All HRCT patterns have reduced FVC but significant reduction with RGHT 
pattern.  
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VII. CONCLUSION 
Altered DLCO may be the first and only abnormality found  in early stage of 
Diffuse parenchymal lung diseases. The earlier discussed studies show the correlation 
between individual collagen vascular disease and pulmonary function testing. But this 
study focuses on evaluation of Diffusing capacity for carbon monoxide among patients 
with  Diffuse parenchymal lung diseases in all classified Collagen vascular diseases 
showing various HRCT pattern  abnormalities and correlate the same with spirometry. 
Among the various combinations of HRCT patterns in Collagen vascular diseases 
presence of Honeycombing is associated with significant severe reduction in DLCO and 
DLCOHb with varying grades of severity in Forced vital capacity.When individual 
HRCT patterns analysed Honey combing and Traction bronchiectasis patterns  have 
significant severe reduction in DLCO and DLCOHb with varying grades of spirometry 
severity . 
When DLCO and DLCOHb are within normal limits the reduction in Forced vital 
capacity has to be correlated with age factor. 
In summary DLCO and DLCOHb are in significant association with spirometry. 
The percent predicted DLCO and DLCOHb best reflect the extent of Honeycombing 
which is considered as fibrotic index in Diffuse parenchymal lung diseases with Collagen 
vascular diseases, and therefore should be measured in routine evaluations. 
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So we conclude DLCO and DLCOHb in collagen vascular disease will be of use 
in initial evaluation of severity of collagen vascular disease as well as to assess the 
response to treatment in these disorders. 
 
 
 
 
 
Fig:A Ground Glass Opacity &Traction  Bronchiectasis 
 
 
Fig:B  Bilateral Reticular opacities 
 
Fig:C Reticulonodular with Honeycombing 
 
 
Fig:D Reticulonodular with Dilated Esophagus 
  
 
 
 
 
 
 
Fig 1. Age group 
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Fig 3. Disease classification 
 
 
 
 
 
 
RN-Reticulo Nodular, GGO-Ground Glass Opacity, RNG- Reticulo Nodular with Ground Glass 
Opacity , RGHT- Reticular, Ground  glass opacity,  Honeycombing & Traction bronchiectasis, 
RH-Reticular & Honeycombing, RGH-Reticular, Ground  glass opacity& Honeycombing 
Fig 4. HRCT Patterns 
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R-Reticular,GGO-Ground glass Opacity ,H-Honey combing,T-Traction bronchiectasis, N-Nodular 
 
Fig 5. HRCT Individual patterns 
 
 
 
 
 
 
 
Fig 6. FVC 
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Fig 7. Diffusing capacity 
 
Fig 7. Diffusing capacity 
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Fig.8 FVC VS DLCO&DLCOHb 
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RN-Reticulo Nodular, GGO-Ground Glass Opacity, RNG- Reticulo Nodular with Ground Glass 
Opacity , RGHT- Reticular, Ground  glass opacity,  Honeycombing & Traction bronchiectasis, 
RH-Reticular & Honeycombing, RGH-Reticular, Ground  glass opacity& Honeycombing 
Fig 9. HRCT Vs DLCO 
 
 
  
 
 
 
 
 
RN-Reticulo Nodular, GGO-Ground Glass Opacity, RNG- Reticulo Nodular with Ground Glass 
Opacity , RGHT- Reticular, Ground  glass opacity,  Honeycombing & Traction bronchiectasis, 
RH-Reticular & Honeycombing, RGH-Reticular, Ground  glass opacity& Honeycombing 
Fig 10. HRCT Vs DLCOHb 
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Fig 11. INDIVIDUAL HRCT PATTERN Vs DLCO&DLCOHb 
 
FIG 12. COLLINS AUTOMATED SYSTEM FOR PERFORMING DLCO  
VIII. ABBREVIATION 
ATS  American Thoracic Society   
CVD   Collagen Vascular Disease 
DIP   Diffuse Interstitial Pneumonia 
DLCO  Diffusing Capacity for Carbon Monoxide 
DLCO/VA  Diffusing capacity for carbon monoxide per unit of alveolar volume 
DPLD  Diffuse Parenchymal Lung Disease 
FEV1  Forced expiratory volume in 1 second 
FVC   Forced vital capacity 
GGO  Ground Glass Opacity 
Hb  Haemoglobin 
HRCT  High Resolution Computerised Tomography 
ILD  Interstitial lung diseases 
KCO   Transfer coefficient of the lung (DLCO/VA) 
LIP   Lymphocytic Interstitial Pneumonitis 
MCTD Mixed Connective Tissue Disease  
NSIP   Non-Specific Interstitial Pneumonitis 
PFT   Pulmonary Function Test  
PM/DM Polymyositis/Dermatmyositis 
RA   Rheumatoid Arthritis 
RBILD  Respiratory Bronchiolitis Interstitial Lung Disease 
SLE  Systemic Lupus Erythematosus 
SS  Systemic Sclerosis 
UIP  Usual interstitial pneumonia 
VA  Alveolar Volume 
VD   Dead space volume 
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X. MASTER CHART 
 
 
SNO ID NAME AGE Sex Diagnosis FVC Restriction DLCO Reported DLCOHb Reported HRCT 
1 21146 Dhanamal 68 F SS 76 Mild 22 Severe 23 Severe RGHT 
2 16922 Saroja 60 F SS 51  Moderate 22 Severe 23 Severe RN 
3 24742 Annamalai 56 M SS 62 Moderate 32 Severe 32 Severe RGH 
4 20320 Perumal 48 M SS 90 Normal 63 Moderate 69 Mild GGO 
5 15165 Desingh 46 M SS 50 Moderate 59 Moderate 64 Moderate RN 
6 19434 Lalitha 53 F SS 67 Mild 25 Severe 27 Severe RGN 
7 21699 Ranjitha 16 F SS 60 Moderate 42 Severe 50 Moderate RH 
8 50167  Selvi 37 F SS 33 Severe 15 Severe 16 Severe RGHT 
9 23083 Alli 42 F SS 45 Moderate 26 Severe 30 Severe RN 
10 24127 Chellamma 40 F SS 95 Normal 81 Normal 88 Normal RN 
11 23874 Devaki 45 F SS 80 Normal 69 Mild 74 Mild GGO 
12 24609 Devi 45 F SS 52 Moderate 23 Severe 25 Severe RGHT 
13 20788 Rajeswari 32 F SS 85 Normal 61 Moderate 66 Mild GGO 
14 17631 Venkatesan 50 M SS 54 Moderate 57 Moderate 59 Moderate RN 
15 21876 Chinnamal 30 F SS 50 Moderate 39 Severe 40 Severe RH 
16 23775 Anusya 31 F SS 70 Mild 73 Mild 79 Mild GGO 
17 21607 Kanniappan 33 M RA 87 Normal 90 Normal 111 Normal RN 
18 9626 Dhillaiammal 50 F RA 56 Moderate 58 Moderate 63 Moderate RGN 
19 16325 Pankajam 63 F RA 47 Moderate 108 Normal 123 Normal RGN 
20 48044 Pakirisamy 62 M RA 21 Severe 38 Severe 38 Severe RGHT 
21 22044 Prakasam 65 M RA 74 Mild 107 Normal 114 Normal GGO 
22 22192 Gopal 58 M RA 44 Moderate 23 Severe 28 Severe RN 
23 21774 Varadhan 56 M RA 84 Normal 67 Mild 72 Mild RN 
24 16872 Sundari 74 F RA 62 Moderate 24 Severe 26 Severe RN 
25 22096 Dhanalakshmi 48 F RA 64 Moderate 37 Severe 36 Severe RN 
26 22234 Dhanapackiam 40 F RA 89 Normal 83 Normal 85 Normal GGO 
27 67507 Murugaiyan 43 M RA 65 Mild 58 Moderate 58 Moderate RN 
28 15890 Selvakumar 40 M RA 77 Mild 22 Severe 25 Severe RN 
29 50229 Shakeela 30 F SLE 42 Moderate 24 Severe 28 Severe RGN 
30 13175 Vasantha 48 F SLE 44 Moderate 29 Severe 30 Severe RN 
31 49759 Kala 42 F PM/DM 53 Moderate 29 Severe 30 Severe RGN 
32 9449 Jeyapaul 21 M PM/DM 52 Moderate 59 Moderate 60 Moderate GGO 
33 23128 Aruna sundar 38 F MCTD 88 Normal 66 Mild 75 Mild RN 
34 16888 Menaka 23 F MCTD 27 Severe 11 Severe 11 Severe RGN 
35 23163 Gunaselvi 26 F MCTD 34 Severe 11 Severe 12 Severe RGHT 
36 22099 Kannika 36 F Sjogrens 50 Moderate 63 Mild 66 Mild RN 
 
XI. KEY TO THE MASTER CHART 
SEX 
M - Male 
F - Female 
DIGNOSIS 
SS    - Systemic sclerosis 
RA   - Rheumatoid arthritis 
SLE  - Systemic lupus Erythematosus 
PM/DM - Polymyositis/Dermatomyositis 
MCTD   - Mixed connective tissue disease 
FVC REPORTED 
Normal -  Normal FVC 
Mild  - Mild restriction 
Moderate -  Moderate restriction 
Severe  - Severe restriction 
DLCO&DLCOHb REPORTED 
Normal - Normal DLCO &DLCOHb 
Mild  - Mildly reduced diffusing capacity 
Moderate - Moderately reduced diffusing capacity  
Severe  - Severely   reduced diffusing capacity 
HRCT PATTERNS 
RN  - Reticulo Nodular 
GGO  - Ground Glass Opacity 
RNG  -  Reticulo Nodular with Ground Glass Opacity  
RGHT  -  Reticular, Ground  glass opacity,  Honeycombing & Traction  
 bronchiectasis 
RH  - Reticular & Honeycombing 
RGH  - Reticular, Ground  glass opacity& Honeycombing 
 
